Shekeeb S Mohammad1,2, Hannah Jones3, Martin Hong2, Margherita Nosadini1,4, Cynthia Sharpe3, Sekhar C Pillai1, Fabienne Brilot1, Russell C Dale1,2. 1. Neuroimmunology Group, Institute for Neuroscience and Muscle Research, The Children's Hospital at Westmead, Sydney, Australia. 2. The Children's Hospital at Westmead Clinical School, University of Sydney, Sydney, Australia. 3. Department of Neuroservices, Starship Children's Hospital, Auckland, New Zealand. 4. Paediatric Neurology Unit, Department of Woman's and Child's Health, University Hospital of Padua, Padua, Italy.
Abstract
AIM: We performed the first study on the perceived benefit and adverse effects of symptomatic management in children with anti-N-methyl-d-aspartate receptor (NMDAR) encephalitis. METHOD: A retrospective chart review was undertaken at two tertiary paediatric hospitals in Australia and New Zealand. We included 27 children (12 males, 15 females; mean age at admission 7y 1mo) with anti-NMDAR antibodies in serum or cerebrospinal fluid with a typical clinical syndrome. RESULTS: Only two out of 27 patients were white, whereas 16 out of 27 patients were from the Pacific Islands/New Zealand Maori. The mean duration of admission was 69 days (10-224d) and 48% of patients (13/27) needed treatment in an intensive care setting. A mean of eight medications per patient was used for symptomatic management. Symptoms treated were agitation (n=25), seizures (n=24), movement disorders (n=23), sleep disruption (n=17), psychiatric symptoms (n=10), and dysautonomia (n=four). The medications used included five different benzodiazepines (n=25), seven anticonvulsants (n=25), eight sedatives and sleep medications (n=23), five antipsychotics (n=12), and five medications for movement disorders (n=10). Sedative and sleep medications other than benzodiazepines were the most effective, with a mean benefit of 67.4% per medication and a mean adverse effect-benefit ratio of 0.04 per medication. Antipsychotic drugs were used for a short duration (median 9d), and had the poorest mean benefit per medication of 35.4% and an adverse effect-benefit ratio of 2.0 per medication. INTERPRETATION: Long-acting benzodiazepines, anticonvulsants, and clonidine can treat multiple symptoms. Patients with anti-NMDAR encephalitis appear vulnerable to antipsychotic-related adverse effects. Pacific Islanders appear to have a vulnerability to anti-NMDAR encephalitis in our region.
AIM: We performed the first study on the perceived benefit and adverse effects of symptomatic management in children with anti-N-methyl-d-aspartate receptor (NMDAR) encephalitis. METHOD: A retrospective chart review was undertaken at two tertiary paediatric hospitals in Australia and New Zealand. We included 27 children (12 males, 15 females; mean age at admission 7y 1mo) with anti-NMDAR antibodies in serum or cerebrospinal fluid with a typical clinical syndrome. RESULTS: Only two out of 27 patients were white, whereas 16 out of 27 patients were from the Pacific Islands/New Zealand Maori. The mean duration of admission was 69 days (10-224d) and 48% of patients (13/27) needed treatment in an intensive care setting. A mean of eight medications per patient was used for symptomatic management. Symptoms treated were agitation (n=25), seizures (n=24), movement disorders (n=23), sleep disruption (n=17), psychiatric symptoms (n=10), and dysautonomia (n=four). The medications used included five different benzodiazepines (n=25), seven anticonvulsants (n=25), eight sedatives and sleep medications (n=23), five antipsychotics (n=12), and five medications for movement disorders (n=10). Sedative and sleep medications other than benzodiazepines were the most effective, with a mean benefit of 67.4% per medication and a mean adverse effect-benefit ratio of 0.04 per medication. Antipsychotic drugs were used for a short duration (median 9d), and had the poorest mean benefit per medication of 35.4% and an adverse effect-benefit ratio of 2.0 per medication. INTERPRETATION: Long-acting benzodiazepines, anticonvulsants, and clonidine can treat multiple symptoms. Patients with anti-NMDAR encephalitis appear vulnerable to antipsychotic-related adverse effects. Pacific Islanders appear to have a vulnerability to anti-NMDAR encephalitis in our region.
Authors: Sukhvir K Wright; Richard E Rosch; Max A Wilson; Manoj A Upadhya; Divya R Dhangar; Charlie Clarke-Bland; Tamara T Wahid; Sumanta Barman; Norbert Goebels; Jakob Kreye; Harald Prüss; Leslie Jacobson; Danielle S Bassett; Angela Vincent; Stuart D Greenhill; Gavin L Woodhall Journal: Commun Biol Date: 2021-09-20
Authors: Hesham Abboud; John Probasco; Sarosh R Irani; Beau Ances; David R Benavides; Michael Bradshaw; Paulo Pereira Christo; Russell C Dale; Mireya Fernandez-Fournier; Eoin P Flanagan; Avi Gadoth; Pravin George; Elena Grebenciucova; Adham Jammoul; Soon-Tae Lee; Yuebing Li; Marcelo Matiello; Anne Marie Morse; Alexander Rae-Grant; Galeno Rojas; Ian Rossman; Sarah Schmitt; Arun Venkatesan; Steven Vernino; Sean J Pittock; Maarten Titulaer Journal: J Neurol Neurosurg Psychiatry Date: 2021-03-01 Impact factor: 13.654
Authors: R Rosello; B Girela-Serrano; M Lim; S Taylor; S Gómez; B Baig Journal: Eur Arch Psychiatry Clin Neurosci Date: 2021-07-17 Impact factor: 5.270